Skip to main content
. 2012 Oct-Dec;2(4):501–504. doi: 10.4103/2045-8932.105039

Figure 1.

Figure 1

Serum levels of Endothelin-1 (ET-1) and hepatitis C viral (HCV) load in 16 patients receiving IFNα2a (180μg subcutaneously once weekly) and weight-based oral Ribavirin (1000-1200 mg daily) over a 6 month period. n = 16, M:F10:6, age range (mean): 24 years 5 months - 61 years 1 month (45 years, 2 months). (A) Patient 1 - hepatitis C viral suppression from week 8 of IFN therapy that was maintained through treatment and level of ET-1 that became elevated peaking at week 4 of treatment. (B) Patient 2 - hepatitis C viral suppression from week 4 of IFN therapy that was maintained through treatment and level of ET-1 that showed a considerable rise at week 8 and was even further elevated at 24 weeks. (C) Patients 3 - 13 - patients who responded well to IFN therapy with viral suppression by 24 weeks but in whom ET-1 levels did not become elevated. (D) Patients 14 - 16 - patients who did not respond to IFN therapy and in whom ET-1 levels were not elevated. Two patients had treatment up to week 12 and one patient continued to receive treatment up until week 24.